Inscrição na biblioteca: Guest
Critical Reviews™ in Neurobiology

Publicou 3 edições por ano

ISSN Imprimir: 0892-0915

ISSN On-line: 2375-0014

SJR: 0.121

Behavioral Effects of Cannabinoid Agents in Animals

Volume 13, Edição 3, 1999, pp. 243-281
DOI: 10.1615/CritRevNeurobiol.v13.i3.20
Get accessGet access

RESUMO

Two subtypes of cannabinoid receptors have been identified to date, the CB, receptor, essentially located in the CNS, but also in peripheral tissues, and the CB2 receptor, found only at the periphery. The identification of Δ9-tetrahydrocannabinol (Δ9-THC) as the major active component of marijuana (Cannabis sativa), the recent emergence of potent synthetic ligands and the identification of anandamide and sn-2 arachidonylglycerol as putative endogenous ligands for cannabinoid receptors in the brain, have contributed to advancing cannabinoid pharmacology and approaching the neurobiological mechanisms involved in physiological and behavioral effects of cannabinoids. Most of the agonists exhibit nonselective affinity for CB1/CB2 receptors, and Δ9-THC and anandamide probably act as partial agonists. Some recently synthesized molecules are highly selective for CB2 receptors, whereas selective agonists for the CB1 receptors are not yet available. A small number of antagonists exist that display a high selectivity for either CB1 or CB2 receptors. Cannabinomimetics produce complex pharmacological and behavioral effects that probably involve numerous neuronal substrates. Interactions with dopamine, acetylcholine, opiate, and GABAergic systems have been demonstrated in several brain structures. In animals, cannabinoid agonists such as Δ9-THC, WIN 55,212-2, and CP 55,940 produce a characteristic combination of four symptoms, hypothermia, analgesia, hypoactivity, and catalepsy. They are reversed by the selective CB1 receptor antagonist, SR 141716, providing good evidence for the involvement of CB1-related mechanisms. Anandamide exhibits several differences, compared with other agonists. In particular, hypothermia, analgesia, and catalepsy induced by this endogenous ligand are not reversed by SR 141716. Cannabinoid-related processes seem also involved in cognition, memory, anxiety, control of appetite, emesis, inflammatory, and immune responses. Agonists may induce biphasic effects, for example, hyperactivity at low doses and severe motor deficits at larger doses. Intriguingly, although cannabis is widely used as recreational drug in humans, only a few studies revealed an appetitive potential of cannabimimetics in animals, and evidence for aversive effects of Δ9-THC, WIN 55,212-2, and CP 55,940 is more readily obtained in a variety of tests. The selective blockade of CB1 receptors by SR 141716 impaired the perception of the appetitive value of positive reinforcers (food, cocaine, morphine) and reduced the motivation for sucrose, beer and alcohol consumption, indicating that positive incentive and/or motivational processes could be under a permissive control of CB1-related mechanisms.
There is little evidence that cannabinoid systems are activated under basal conditions. However, by using SR 141716 as a tool, a tonic involvement of a CB1-mediated cannabinoid link has been demonstrated, notably in animals suffering from chronic pain, faced with anxiogenic stimuli or highly motivational reinforcers. Some effects of SR 141716 also suggest that CB1-related mechanisms exert a tonic control on cognitive processes.
Extensive basic research is still needed to elucidate the roles of cannabinoid systems, both in the brain and at the periphery, in normal physiology and in diseases. Additional compounds, such as selective CB1 receptor agonists, ligands that do not cross the blood brain barrier, drugs interfering with synthesis, degradation or uptake of endogenous ligand(s) of CB receptors, are especially needed to understand when and how cannabinoid systems are activated. In turn, new therapeutic strategies would likely to emerge.

CITADO POR
  1. Tzavara Eleni T, Davis Richard J, Perry Kenneth W, Li Xia, Salhoff Craig, Bymaster Frank P, Witkin Jeffrey M, Nomikos George G, The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions, British Journal of Pharmacology, 138, 4, 2003. Crossref

  2. Fattore Liana, Spano M. Sabrina, Deiana Serena, Melis Valeria, Cossu Gregorio, Fadda Paola, Fratta Walter, An endocannabinoid mechanism in relapse to drug seeking: A review of animal studies and clinical perspectives, Brain Research Reviews, 53, 1, 2007. Crossref

  3. Rodríguez-Gaztelumendi Antonio, Rojo Mª Luisa, Pazos Angel, Díaz Alvaro, Altered CB1receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine, Journal of Neurochemistry, 108, 6, 2009. Crossref

  4. Bialuk Izabela, Winnicka Maria M., AM251, cannabinoids receptors ligand, improves recognition memory in rats, Pharmacological Reports, 63, 3, 2011. Crossref

  5. Geresu Berhanu, Onaivi Emmanuel, Engidawork Ephrem, Behavioral evidence for the interaction between cannabinoids and Catha edulis F. (Khat) in mice, Brain Research, 1648, 2016. Crossref

  6. Garry Aurélia, Rigourd Virginie, Amirouche Ammar, Fauroux Valérie, Aubry Sylvie, Serreau Raphaël, Cannabis and Breastfeeding, Journal of Toxicology, 2009, 2009. Crossref

  7. Lorivel T., Hilber P., Motor effects of delta 9 THC in cerebellar Lurcher mutant mice, Behavioural Brain Research, 181, 2, 2007. Crossref

  8. Friemel Chris M, Zimmer Andreas, Schneider Miriam, The CB1 Receptor as an Important Mediator of Hedonic Reward Processing, Neuropsychopharmacology, 39, 10, 2014. Crossref

  9. Shen Erica Y., Ali Syed F., Meyer Jerrold S., Chronic administration of THC prevents the behavioral effects of intermittent adolescent MDMA administration and attenuates MDMA-induced hyperthermia and neurotoxicity in rats, Neuropharmacology, 61, 8, 2011. Crossref

  10. Yazulla Stephen, Endocannabinoids in the retina: From marijuana to neuroprotection, Progress in Retinal and Eye Research, 27, 5, 2008. Crossref

  11. Meil William, Boja John, The Dopamine Transporter and Addiction, in Neurochemistry of Abused Drugs, 2007. Crossref

  12. De Vries Taco J., de Vries Wendy, Janssen Mieke C.W., Schoffelmeer Anton N.M., Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A, Behavioural Brain Research, 161, 1, 2005. Crossref

  13. Huerta Miguel, Ortiz-Mesina Mónica, Trujillo Xóchitl, Sánchez-Pastor Enrique, Vásquez Clemente, Castro Elena, Velasco Raymundo, Montoya-Pérez Rocío, Onetti Carlos, Effects of Cannabinoids on Caffeine Contractures in Slow and Fast Skeletal Muscle Fibers of the Frog, Journal of Membrane Biology, 229, 2, 2009. Crossref

  14. Campolongo Patrizia, Morena Maria, Scaccianoce Sergio, Trezza Viviana, Chiarotti Flavia, Schelling Gustav, Cuomo Vincenzo, Roozendaal Benno, Novelty-Induced Emotional Arousal Modulates Cannabinoid Effects on Recognition Memory and Adrenocortical Activity, Neuropsychopharmacology, 38, 7, 2013. Crossref

  15. Bortolato Marco, Piomelli Daniele, Chapter 4.5 The endocannabinoid system and anxiety responses, in Handbook of Anxiety and Fear, 17, 2008. Crossref

  16. Tham Shao M, Angus James A, Tudor Elizabeth M, Wright Christine E, Synergistic and additive interactions of the cannabinoid agonist CP55,940 with μ opioid receptor and α 2 -adrenoceptor agonists in acute pain models in mice, British Journal of Pharmacology, 144, 6, 2005. Crossref

  17. Viggiano Davide, The hyperactive syndrome: Metanalysis of genetic alterations, pharmacological treatments and brain lesions which increase locomotor activity, Behavioural Brain Research, 194, 1, 2008. Crossref

  18. Malone Daniel T., Long Leonora E., Taylor David A., The effect of SR 141716 and apomorphine on sensorimotor gating in Swiss mice, Pharmacology Biochemistry and Behavior, 77, 4, 2004. Crossref

  19. Järbe Torbjörn U.C, Lamb Richard J, Liu Qian, Makriyannis Alexandros, (R)-Methanandamide and Δ9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A, European Journal of Pharmacology, 466, 1-2, 2003. Crossref

  20. Pozzoli Giacomo, Tringali Giuseppe, Vairano Mauro, D'Amico Monia, Navarra Pierluigi, Martire Maria, Cannabinoid agonist WIN55,212-2 induces apoptosis in cerebellar granule cells via activation of the CB1 receptor and downregulation of bcl-xL gene expression, Journal of Neuroscience Research, 83, 6, 2006. Crossref

  21. Scarpelli Rita, Sasso Oscar, Piomelli Daniele, ADouble Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation, ChemMedChem, 11, 12, 2016. Crossref

  22. Staley Julie, Cosgrove Kelly, Neurochemistry of Drug Abuse, in Drug Abuse Handbook, Second Edition, 2006. Crossref

  23. Nazzaro Cristiano, Greco Barbara, Cerovic Milica, Baxter Paul, Rubino Tiziana, Trusel Massimo, Parolaro Daniela, Tkatch Tatiana, Benfenati Fabio, Pedarzani Paola, Tonini Raffaella, SK channel modulation rescues striatal plasticity and control over habit in cannabinoid tolerance, Nature Neuroscience, 15, 2, 2012. Crossref

  24. Dogrul Ahmet, Gul Husamettin, Akar Ahmet, Yildiz Oguzhan, Bilgin Ferruh, Guzeldemir Erdal, Topical cannabinoid antinociception: synergy with spinal sites, Pain, 105, 1, 2003. Crossref

  25. Rodgers R. J., Evans P. M., Murphy A., Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-na??ve and plus-maze-experienced mice, Behavioural Pharmacology, 16, 5-6, 2005. Crossref

  26. Sarne Yosef, Asaf Fadi, Fishbein Miriam, Gafni Mikhal, Keren Ora, The dual neuroprotective-neurotoxic profile of cannabinoid drugs, British Journal of Pharmacology, 163, 7, 2011. Crossref

  27. López Hassan H., Webb Sarah A., Nash Sean, Cannabinoid receptor antagonism increases female sexual motivation, Pharmacology Biochemistry and Behavior, 92, 1, 2009. Crossref

  28. Hayase T., Yamamoto Y., Yamamoto K., Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands, Behavioural Pharmacology, 16, 5-6, 2005. Crossref

  29. Melis Maria Rosaria, Succu Salvatora, Mascia Maria Stefania, Sanna Fabrizio, Melis Tiziana, Castelli Maria Paola, Argiolas Antonio, The cannabinoid receptor antagonist SR-141716A induces penile erection in male rats: Involvement of paraventricular glutamic acid and nitric oxide, Neuropharmacology, 50, 2, 2006. Crossref

  30. Tzavara Eleni T, Perry Kenneth W, Rodriguez Dana E, Bymaster Frank P, Nomikos George G, The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus, European Journal of Pharmacology, 426, 3, 2001. Crossref

  31. Kalbasi Anaraki Dina, Sianati Setareh, Sadeghi Mahsa, Ghasemi Mehdi, Javadi Parvin, Ejtemaei Mehr Shahram, Dehpour Ahmad Reza, Modulation by female sex hormones of the cannabinoid-induced catalepsy and analgesia in ovariectomized mice, European Journal of Pharmacology, 586, 1-3, 2008. Crossref

  32. Palermo Francesco Alessandro, Cardinaletti Gloriana, Cocci Paolo, Tibaldi Emilio, Polzonetti-Magni Alberta, Mosconi Gilberto, Effects of dietary nucleotides on acute stress response and cannabinoid receptor 1 mRNAs in sole, Solea solea, Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology, 164, 3, 2013. Crossref

  33. Viveros María-Paz, Marco Eva-María, Llorente Ricardo, López-Gallardo Meritxell, Endocannabinoid System and Synaptic Plasticity: Implications for Emotional Responses, Neural Plasticity, 2007, 2007. Crossref

  34. Parker Linda A., Kemp Stephen W. P., Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: An animal model of anticipatory nausea and vomiting (ANV), Neuroreport, 12, 4, 2001. Crossref

  35. Nasehi Mohammad, Sahebgharani Mousa, Haeri-Rohani Ali, Zarrindast Mohammad Reza, Effects of cannabinoids infused into the dorsal hippocampus upon memory formation in 3-days apomorphine-treated rats, Neurobiology of Learning and Memory, 92, 3, 2009. Crossref

  36. Howlett Allyn C, The cannabinoid receptors, Prostaglandins & Other Lipid Mediators, 68-69, 2002. Crossref

  37. Ruggieri Valentina, Vitale Giovanni, Filaferro Monica, Frigeri Claudio, Pini Luigi A., Sandrini Maurizio, The antinociceptive effect of acetylsalicylic acid is differently affected by a CB1 agonist or antagonist and involves the serotonergic system in rats, Life Sciences, 86, 13-14, 2010. Crossref

  38. Parsons L.H., Δ9-THC, in Encyclopedia of Behavioral Neuroscience, 2010. Crossref

  39. González-Cuevas Gustavo, Aujla Harinder, Martin-Fardon Rémi, López-Moreno José Antonio, Navarro Miguel, Weiss Friedbert, Subchronic Cannabinoid Agonist (WIN 55,212-2) Treatment during Cocaine Abstinence Alters Subsequent Cocaine Seeking Behavior, Neuropsychopharmacology, 32, 11, 2007. Crossref

  40. Zarrindast Mohammad Reza, Nasehi Mohammad, Piri Morteza, Bina Payvand, Anxiety-like behavior induced by histaminergic agents can be prevented by cannabinoidergic WIN55,212-2 injected into the dorsal hippocampus in mice, Pharmacology Biochemistry and Behavior, 94, 3, 2010. Crossref

  41. Solinas M, Panlilio L V, Goldberg S R, Exposure to Δ-9-Tetrahydrocannabinol (THC) Increases Subsequent Heroin Taking but not Heroin's Reinforcing Efficacy: A Self-Administration Study in Rats, Neuropsychopharmacology, 29, 7, 2004. Crossref

  42. Steindel Frauke, Lerner Raissa, Häring Martin, Ruehle Sabine, Marsicano Giovanni, Lutz Beat, Monory Krisztina, Neuron-type specific cannabinoid-mediated G protein signalling in mouse hippocampus, Journal of Neurochemistry, 124, 6, 2013. Crossref

  43. Vlachou Styliani, Nomikos George G., Panagis George, CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat, Psychopharmacology, 179, 2, 2005. Crossref

  44. Miliano Cristina, Serpelloni Giovanni, Rimondo Claudia, Mereu Maddalena, Marti Matteo, De Luca Maria Antonietta, Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants, Frontiers in Neuroscience, 10, 2016. Crossref

  45. Klooker T. K., Leliefeld K. E. M., Van Den Wijngaard R. M., Boeckxstaens G. E. E., The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients, Neurogastroenterology & Motility, 23, 1, 2011. Crossref

  46. Juszczak Grzegorz R., Swiergiel Artur H., Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: Animal and human studies, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33, 2, 2009. Crossref

  47. Borcel Erika, Pérez-Alvarez Laura, de Ceballos Marı́a L, Ramirez Belén G, Marco Eva M, Fernández Beatriz, Rubio Marina, Guaza Carmen, Viveros M-Paz, Functional responses to the cannabinoid agonist WIN 55,212-2 in neonatal rats of both genders: influence of weaning, Pharmacology Biochemistry and Behavior, 78, 3, 2004. Crossref

  48. Ghozland Sandy, Aguado Fernando, Espinosa-Parrilla Juan F., Soriano Eduardo, Maldonado Rafael, Spontaneous network activity of cerebellar granule neurons: impairment byin vivochronic cannabinoid administration, European Journal of Neuroscience, 16, 4, 2002. Crossref

  49. Zhang Rui-san, He Zhen, Jin Wei-dong, Wang Rui, Effects of the cannabinoid 1 receptor peptide ligands hemopressin, (m)RVD-hemopressin(α) and (m)VD-hemopressin(α) on memory in novel object and object location recognition tasks in normal young and Aβ 1–42 -treated mice, Neurobiology of Learning and Memory, 134, 2016. Crossref

  50. Antonelli T, Tanganelli S, Tomasini M.C, Finetti S, Trabace L, Steardo L, Sabino V, Carratu M.R, Cuomo V, Ferraro L, Long-term effects on cortical glutamate release induced by prenatal exposure to the cannabinoid receptor agonist (r)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone: an in vivo microdialysis study in the awake rat, Neuroscience, 124, 2, 2004. Crossref

  51. Witkin J. M., Tzavara E. T., Nomikos G. G., A role for cannabinoid CB1 receptors in mood and anxiety disorders, Behavioural Pharmacology, 16, 5-6, 2005. Crossref

  52. Marco Eva María, Adriani Walter, Canese Rossella, Podo Franca, Viveros Maria Paz, Laviola Giovanni, Enhancement of endocannabinoid signalling during adolescence: Modulation of impulsivity and long-term consequences on metabolic brain parameters in early maternally deprived rats, Pharmacology Biochemistry and Behavior, 86, 2, 2007. Crossref

  53. Berry Elliot M, Mechoulam Raphael, Tetrahydrocannabinol and endocannabinoids in feeding and appetite, Pharmacology & Therapeutics, 95, 2, 2002. Crossref

  54. Kathuria Satish, Gaetani Silvana, Fegley Darren, Valiño Fernando, Duranti Andrea, Tontini Andrea, Mor Marco, Tarzia Giorgio, Rana Giovanna La, Calignano Antonio, Giustino Arcangela, Tattoli Maria, Palmery Maura, Cuomo Vincenzo, Piomelli Daniele, Modulation of anxiety through blockade of anandamide hydrolysis, Nature Medicine, 9, 1, 2003. Crossref

  55. Roohbakhsh Ali, Keshavarz Samaneh, Hasanein Parisa, Rezvani Mohammad Ebrahim, Moghaddam Akbar Hajizadeh, Role of Endocannabinoid System in the Ventral Hippocampus of Rats in the Modulation of Anxiety-Like Behaviours, Basic & Clinical Pharmacology & Toxicology, 105, 5, 2009. Crossref

  56. Jockers-ScherüBl Maria C., Matthies Uta, Danker-Hopfe Heidi, Lang Undine E., Mahlberg Richard, Hellweg Rainer, Chronic Cannabis Abuse Raises Nerve Growth Factor Serum Concentrations in Drug-Naive Schizophrenic Patients, Journal of Psychopharmacology, 17, 4, 2003. Crossref

  57. Järbe Torbjörn U.C., Andrzejewski Matthew E., DiPatrizio Nicholas V., Interactions between the CB1 receptor agonist Δ9-THC and the CB1 receptor antagonist SR-141716 in rats, Pharmacology Biochemistry and Behavior, 73, 4, 2002. Crossref

  58. El Khoury Marie-Anne, Gorgievski Victor, Moutsimilli Larissa, Giros Bruno, Tzavara Eleni T., Interactions between the cannabinoid and dopaminergic systems: Evidence from animal studies, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 38, 1, 2012. Crossref

  59. Argiolas Antonio, Melis Maria Rosaria, Central control of penile erection: Role of the paraventricular nucleus of the hypothalamus, Progress in Neurobiology, 76, 1, 2005. Crossref

  60. Witkin Jeffrey M., Tzavara Eleni T., Davis Richard J., Li Xia, Nomikos George G., A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders, Trends in Pharmacological Sciences, 26, 12, 2005. Crossref

  61. Julian M.D., Martin A.B., Cuellar B., Rodriguez De Fonseca F., Navarro M., Moratalla R., Garcia-Segura L.M., Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia, Neuroscience, 119, 1, 2003. Crossref

  62. Maccarrone Mauro, Valverde Olga, Barbaccia Maria L., Castañé Anna, Maldonado Rafael, Ledent Catherine, Parmentier Marc, Finazzi-Agrò Alessandro, Age-related changes of anandamide metabolism in CB1cannabinoid receptor knockout mice: correlation with behaviour, European Journal of Neuroscience, 15, 7, 2002. Crossref

  63. Muller Patrick Y., Dambach Donna, Gemzik Brian, Hartmann Andreas, Ratcliffe Sian, Trendelenburg Christian, Urban Laszlo, Integrated risk assessment of suicidal ideation and behavior in drug development, Drug Discovery Today, 20, 9, 2015. Crossref

  64. Muschamp John W, Siviy Stephen M, Behavioral sensitization to amphetamine follows chronic administration of the CB1 agonist WIN 55,212-2 in Lewis rats, Pharmacology Biochemistry and Behavior, 73, 4, 2002. Crossref

  65. Crystal Jonathon D., Maxwell Kenneth W., Hohmann Andrea G., Cannabinoid modulation of sensitivity to time, Behavioural Brain Research, 144, 1-2, 2003. Crossref

  66. Antoniou K., Galanopoulos A., Vlachou S., Kourouli T., Nahmias V., Thermos K., Panagis G., Daifoti Z., Marselos M., Papahatjis D., Spyraki C., Behavioral pharmacological properties of a novel cannabinoid 1???,1???-dithiolane ??8-THC analog, AMG-3, Behavioural Pharmacology, 16, 5-6, 2005. Crossref

  67. Acheson Shawn K., Moore Nicole L.T., Kuhn Cynthia M., Wilson Wilkie A., Swartzwelder H. Scott, The synthetic cannabinoid WIN 55212-2 differentially modulates thigmotaxis but not spatial learning in adolescent and adult animals, Neuroscience Letters, 487, 3, 2011. Crossref

  68. Wegener Nico, Kuhnert Sybille, Thüns Annika, Roese Rasmus, Koch Michael, Effects of acute systemic and intra-cerebral stimulation of cannabinoid receptors on sensorimotor gating, locomotion and spatial memory in rats, Psychopharmacology, 198, 3, 2008. Crossref

  69. Marusich Julie A., Wiley Jenny L., Rimonabant abolishes sensitivity to workload changes in a progressive ratio procedure, Pharmacology Biochemistry and Behavior, 101, 4, 2012. Crossref

  70. Ostadhadi Sattar, Haj-Mirzaian Arya, Nikoui Vahid, Kordjazy Nastaran, Dehpour Ahmad-Reza, Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1receptor inverse agonist AM-251 after physical stress in mice, Clinical and Experimental Pharmacology and Physiology, 43, 2, 2016. Crossref

  71. Duarte Christine, Alonso Richard, Bichet Nicole, Cohen Caroline, Soubrié Philippe, Thiébot Marie-Hélène, Blockade by the Cannabinoid CB1 Receptor Antagonist, Rimonabant (SR141716), of the Potentiation by Quinelorane of Food-Primed Reinstatement of Food-Seeking Behavior, Neuropsychopharmacology, 29, 5, 2004. Crossref

  72. Bambico Francis R., Duranti Andrea, Nobrega José N., Gobbi Gabriella, The fatty acid amide hydrolase inhibitor URB597 modulates serotonin-dependent emotional behaviour, and serotonin1A and serotonin2A/C activity in the hippocampus, European Neuropsychopharmacology, 26, 3, 2016. Crossref

  73. Cha Hye Jin, Lee Kwang-Wook, Eom Jang-Hyeon, Kim Young-Hoon, Shin Jisoon, Yun Jaesuk, Han Kyoungmoon, Kim Hyung Soo, 5-(2-Aminopropyl)benzofuran and phenazepam demonstrate the possibility of dependence by increasing dopamine levels in the brain, Pharmacology Biochemistry and Behavior, 149, 2016. Crossref

  74. Yoshihara Shigemi, Morimoto Hiroshi, Ohori Makoto, Yamada Yumi, Abe Toshio, Arisaka Osamu, The Cannabinoid Receptor Agonist WIN 55212-2 Inhibits Neurogenic Inflammations in Airway Tissues, Journal of Pharmacological Sciences, 98, 1, 2005. Crossref

  75. Scavone J.L., Sterling R.C., Van Bockstaele E.J., Cannabinoid and opioid interactions: Implications for opiate dependence and withdrawal, Neuroscience, 248, 2013. Crossref

  76. Bessa J.M., Oliveira M., Cerqueira J.J., Almeida O.F.X., Sousa N., Age-related qualitative shift in emotional behaviour: Paradoxical findings after re-exposure of rats in the elevated-plus maze, Behavioural Brain Research, 162, 1, 2005. Crossref

  77. Herrera R. Antonio, Oved Joseph H., Reiss Carol Shoshkes, Disruption of IFN-γ–Mediated Antiviral Activity in Neurons: The Role of Cannabinoids, Viral Immunology, 21, 2, 2008. Crossref

  78. Célérier Evelyne, Ahdepil Therese, Wikander Helena, Berrendero Fernando, Nyberg Fred, Maldonado Rafael, Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence, Neuropharmacology, 50, 7, 2006. Crossref

  79. Venderova Katerina, Brown Timothy M., Brotchie Jonathan M., Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus, Experimental Neurology, 194, 1, 2005. Crossref

  80. Darmani N.A., Janoyan J.J., Kumar N., Crim J.L., Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover, Pharmacology Biochemistry and Behavior, 75, 4, 2003. Crossref

  81. Ghose Subroto, Tamminga Carol, Phenomenology and Clinical Science of Schizophrenia, in Handbook of Contemporary Neuropharmacology, 2007. Crossref

  82. Toal Katrina L., Radziwon Kelly E., Holfoth David P., Xu-Friedman Matthew A., Dent Micheal L., Audiograms, gap detection thresholds, and frequency difference limens in cannabinoid receptor 1 knockout mice, Hearing Research, 332, 2016. Crossref

  83. Cippitelli Andrea, Cannella Nazzareno, Braconi Simone, Duranti Andrea, Tontini Andrea, Bilbao Ainhoa, DeFonseca Fernando Rodríguez, Piomelli Daniele, Ciccocioppo Roberto, Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat, Psychopharmacology, 198, 4, 2008. Crossref

  84. McDonald A.J, Mascagni F, Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons, Neuroscience, 107, 4, 2001. Crossref

  85. Watson Christine, Owen Dafydd R., Harding Denise, Kon-I Kana, Lewis Mark L., Mason Helen J., Matsumizu Miyako, Mukaiyama Takasuke, Rodriguez-Lens Margarita, Shima Akiko, Takeuchi Mifune, Tran Isabelle, Young Tim, Optimisation of a novel series of selective CNS penetrant CB2 agonists, Bioorganic & Medicinal Chemistry Letters, 21, 14, 2011. Crossref

  86. Pegorini Simona, Zani Alessia, Braida Daniela, Guerini-Rocco Chiara, Sala Mariaelvina, Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection, British Journal of Pharmacology, 147, 5, 2006. Crossref

  87. Brust John C.M., Cannabis, in Aspects neurologiques de l'addiction, 2007. Crossref

  88. Steiner Alexandre A., Molchanova Alla Y., Dogan M. Devrim, Patel Shreya, Pétervári Erika, Balaskó Márta, Wanner Samuel P., Eales Justin, Oliveira Daniela L., Gavva Narender R., Almeida M. Camila, Székely Miklós, Romanovsky Andrej A., The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors, The Journal of Physiology, 589, 9, 2011. Crossref

  89. Rodgers R. J., Haller J., Halasz J., Mikics E., ‘One-trial sensitization’ to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze, European Journal of Neuroscience, 17, 6, 2003. Crossref

  90. Dyson Alex, Peacock Marcus, Chen Alice, Courade Jean-Philippe, Yaqoob Mohammed, Groarke Alex, Brain Christopher, Loong Yvonne, Fox Alyson, Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat, Pain, 116, 1, 2005. Crossref

  91. RODRÍGUEZ de FONSECA FERNANDO, DEL ARCO IGNACIO, BERMUDEZ-SILVA FRANCISCO JAVIER, BILBAO AINHOA, CIPPITELLI ANDREA, NAVARRO MIGUEL, THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY, Alcohol and Alcoholism, 40, 1, 2005. Crossref

  92. Malone Daniel Thomas, Taylor David Alan, The effect of Δ9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats, Behavioural Brain Research, 166, 1, 2006. Crossref

  93. Tasker Jeffrey G., Chen Chun, Fisher Marc O., Fu Xin, Rainville Jennifer R., Weiss Grant L., Endocannabinoid Regulation of Neuroendocrine Systems, in Endocannabinoids, 125, 2015. Crossref

  94. Schneider M., Koch M., The cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats, Behavioural Pharmacology, 13, 1, 2002. Crossref

  95. Hagemeyer Nora, Goebbels Sandra, Papiol Sergi, Kästner Anne, Hofer Sabine, Begemann Martin, Gerwig Ulrike C., Boretius Susann, Wieser Georg L., Ronnenberg Anja, Gurvich Artem, Heckers Stephan H., Frahm Jens, Nave Klaus‐Armin, Ehrenreich Hannelore, A myelin gene causative of a catatonia‐depression syndrome upon aging, EMBO Molecular Medicine, 4, 6, 2012. Crossref

  96. Hiley C. Robin, Hoi Pui Man, Oleamide: A Fatty Acid Amide Signaling Molecule in the Cardiovascular System?, Cardiovascular Drug Reviews, 25, 1, 2007. Crossref

  97. Arévalo Cristina, de Miguel Rosario, Hernández-Tristán Rafael, Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters, Pharmacology Biochemistry and Behavior, 70, 1, 2001. Crossref

  98. Janova Hana, Arinrad Sahab, Balmuth Evan, Mitjans Marina, Hertel Johannes, Habes Mohamad, Bittner Robert A., Pan Hong, Goebbels Sandra, Begemann Martin, Gerwig Ulrike C., Langner Sönke, Werner Hauke B., Kittel-Schneider Sarah, Homuth Georg, Davatzikos Christos, Völzke Henry, West Brian L., Reif Andreas, Grabe Hans Jörgen, Boretius Susann, Ehrenreich Hannelore, Nave Klaus-Armin, Microglia ablation alleviates myelin-associated catatonic signs in mice, Journal of Clinical Investigation, 128, 2, 2017. Crossref

  99. Hagen E.H., Sullivan R.J., Schmidt R., Morris G., Kempter R., Hammerstein P., Ecology and neurobiology of toxin avoidance and the paradox of drug reward, Neuroscience, 160, 1, 2009. Crossref

  100. Zachariou Margarita, Dissanayake Dilshani W.N., Owen Markus R., Mason Rob, Coombes Stephen, The role of cannabinoids in the neurobiology of sensory gating: A firing rate model study, Neurocomputing, 70, 10-12, 2007. Crossref

  101. Hill Matthew N, Patel Sachin, Carrier Erica J, Rademacher David J, Ormerod Brandi K, Hillard Cecilia J, Gorzalka Boris B, Downregulation of Endocannabinoid Signaling in the Hippocampus Following Chronic Unpredictable Stress, Neuropsychopharmacology, 30, 3, 2005. Crossref

  102. Vlachou Styliani, Stamatopoulou Fygaleia, Nomikos George G., Panagis George, Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine, The International Journal of Neuropsychopharmacology, 11, 07, 2008. Crossref

  103. Lile Joshua A., Kelly Thomas H., Pinsky David J., Hays Lon R., Substitution profile of Δ9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Δ9-tetrahydrocannabinol, Psychopharmacology, 203, 2, 2009. Crossref

  104. López Hassan H., Cannabinoid–hormone interactions in the regulation of motivational processes, Hormones and Behavior, 58, 1, 2010. Crossref

  105. Marı́n S, Marco E, Biscaia M, Fernández B, Rubio M, Guaza C, Schmidhammer H, Viveros M.P, Involvement of the κ-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats, Pharmacology Biochemistry and Behavior, 74, 3, 2003. Crossref

  106. Ferré Sergi, Lluís Carme, Justinova Zuzana, Quiroz César, Orru Marco, Navarro Gemma, Canela Enric I, Franco Rafael, Goldberg Steven R, Adenosine-cannabinoid receptor interactions. Implications for striatal function, British Journal of Pharmacology, 160, 3, 2010. Crossref

  107. van der Stelt Mario, Di Marzo Vincenzo, The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders, European Journal of Pharmacology, 480, 1-3, 2003. Crossref

  108. Rubovitch Vardit, Gafni Mikhal, Sarne Yosef, The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells, Molecular Brain Research, 101, 1-2, 2002. Crossref

  109. Romero Eva M, Fernández Beatriz, Sagredo Onintza, Gomez Nuria, Urigüen Leyre, Guaza Carmen, De Miguel Rosario, Antonio Ramos Jose, Paz Viveros M, Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats, Developmental Brain Research, 136, 2, 2002. Crossref

  110. Kelaï Sabah, Hanoun Naïma, Aufrère Gilles, Beaugé Françoise, Hamon Michel, Lanfumey Laurence, Cannabinoid?serotonin interactions in alcohol-preferring vs. alcohol-avoiding mice, Journal of Neurochemistry, 99, 1, 2006. Crossref

  111. Wegener Nico, Koch Michael, Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment, Brain Research, 1253, 2009. Crossref

  112. Wenger T., Moldrich G., The role of endocannabinoids in the hypothalamic regulation of visceral function, Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), 66, 2-3, 2002. Crossref

  113. FAN SHIH-FANG, YAZULLA STEPHEN, Retrograde endocannabinoid inhibition of goldfish retinal cones is mediated by 2-arachidonoyl glycerol, Visual Neuroscience, 24, 3, 2007. Crossref

  114. Cooper Steven J., Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite, European Journal of Pharmacology, 500, 1-3, 2004. Crossref

  115. Eljaschewitsch Eva, Witting Anke, Mawrin Christian, Lee Thomas, Schmidt Peter M., Wolf Susanne, Hoertnagl Heide, Raine Cedric S., Schneider-Stock Regine, Nitsch Robert, Ullrich Oliver, The Endocannabinoid Anandamide Protects Neurons during CNS Inflammation by Induction of MKP-1 in Microglial Cells, Neuron, 49, 1, 2006. Crossref

  116. Wolff Mary C., Leander J.David, SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task, European Journal of Pharmacology, 477, 3, 2003. Crossref

  117. Bortolato Marco, Aru Gian Nicola, Frau Roberto, Orr� Marco, Luckey Grant Christopher, Boi Gianluca, Gessa Gian Luigi, The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats, Psychopharmacology, 177, 3, 2005. Crossref

  118. Miller Cheryl C, Murray Thomas F, Freeman Kimberly G, Edwards Gaylen L, Cannabinoid agonist, CP 55,940, facilitates intake of palatable foods when injected into the hindbrain, Physiology & Behavior, 80, 5, 2004. Crossref

  119. Fraga D, Zanoni CIS, Rae GA, Parada CA, Souza GEP, Endogenous cannabinoids induce fever through the activation of CB1receptors, British Journal of Pharmacology, 157, 8, 2009. Crossref

  120. Chegini Hamid-Reza, Nasehi Mohammad, Zarrindast Mohammad-Reza, Differential role of the basolateral amygdala 5-HT3 and 5-HT4 serotonin receptors upon ACPA-induced anxiolytic-like behaviors and emotional memory deficit in mice, Behavioural Brain Research, 261, 2014. Crossref

  121. Schechter M., Weller A., Pittel Z., Gross M., Zimmer A., Pinhasov A., Endocannabinoid Receptor Deficiency Affects Maternal Care and Alters the Dam's Hippocampal Oxytocin Receptor and Brain-Derived Neurotrophic Factor Expression, Journal of Neuroendocrinology, 25, 10, 2013. Crossref

  122. Vlachou Styliani, Nomikos George G, Panagis George, WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation, Behavioural Brain Research, 141, 2, 2003. Crossref

  123. Marchese Giorgio, Casti Paola, Ruiu Stefania, Saba PierLuigi, Sanna Angela, Casu GianLuca, Pani Luca, Haloperidol, but not clozapine, produces dramatic catalepsy in Δ9 -THC-treated rats: possible clinical implications, British Journal of Pharmacology, 140, 3, 2003. Crossref

  124. Veale E L, Buswell R, Clarke C E, Mathie A, Identification of a region in the TASK3 two pore domain potassium channel that is critical for its blockade by methanandamide, British Journal of Pharmacology, 152, 5, 2007. Crossref

  125. Fox Helen C., Tuit Keri L., Sinha Rajita, Stress system changes associated with marijuana dependence may increase craving for alcohol and cocaine, Human Psychopharmacology: Clinical and Experimental, 28, 1, 2013. Crossref

  126. Viveros M. P., Llorente R., Moreno E., Marco E. M., Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods, Behavioural Pharmacology, 16, 5-6, 2005. Crossref

  127. Tai Sherrica, Nikas Spyros P., Shukla Vidyanand G., Vemuri Kiran, Makriyannis Alexandros, Järbe Torbjörn U. C., Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist, Psychopharmacology, 232, 15, 2015. Crossref

  128. Gong Jianping, Leonard Claire, Akinshola Babatunde, Onaivi Emmanuel, Lin Zhicheng, Uhl George, Ishiguro Hiroki, Wu Zhang Ping, Chirwa Sanika, Endocannabinoid Receptor Genetics and Marijuana Use, in Endocannabinoids, 2005. Crossref

  129. Harrold Joanne A, Elliott Joanne C, King Peter J, Widdowson Peter S, Williams Gareth, Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food?, Brain Research, 952, 2, 2002. Crossref

  130. Fox Alyson, Kesingland Adam, Gentry Clive, McNair Kara, Patel Sadhana, Urban Laszlo, James Iain, The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain, Pain, 92, 1, 2001. Crossref

  131. Gruber Staci A., Rogowska Jadwiga, Yurgelun-Todd Deborah A., Altered affective response in marijuana smokers: An FMRI study, Drug and Alcohol Dependence, 105, 1-2, 2009. Crossref

  132. Mayer Tzur Alexander, Matar Michael Alex, Kaplan Zeev, Zohar Joseph, Cohen Hagit, Blunting of the HPA-axis underlies the lack of preventive efficacy of early post-stressor single-dose Delta-9-tetrahydrocannabinol (THC), Pharmacology Biochemistry and Behavior, 122, 2014. Crossref

  133. Beinfeld Margery C., Connolly Kelly, Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids, Neuroscience Letters, 301, 1, 2001. Crossref

  134. de Miguel Rosario, Ramos José, Cebeira Maribel, Hernández Mariluz, Fernández-Ruiz Javier, Endocannabinoids and Dopamine-Related Functions in the CNS, in Endocannabinoids, 2005. Crossref

  135. Geresu Berhanu, Khat (Catha edulis F.) and cannabinoids: Parallel and contrasting behavioral effects in preclinical and clinical studies, Pharmacology Biochemistry and Behavior, 138, 2015. Crossref

  136. Crunfli Fernanda, Vilela Fabiana C, Giusti-Paiva Alexandre, Cannabinoid CB1receptors mediate the effects of dipyrone, Clinical and Experimental Pharmacology and Physiology, 42, 3, 2015. Crossref

  137. Avraham Yosefa, Ben-Shushan Dikla, Breuer Aviva, Zolotarev Olga, Okon Avital, Fink Nir, Katz Vered, Berry Elliot M, Very low doses of Δ8-THC increase food consumption and alter neurotransmitter levels following weight loss, Pharmacology Biochemistry and Behavior, 77, 4, 2004. Crossref

  138. Griebel Guy, Stemmelin Jeanne, Scatton Bernard, Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents, Biological Psychiatry, 57, 3, 2005. Crossref

  139. Oropeza Veronica C., Mackie Kenneth, Van Bockstaele Elisabeth J., Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex, Brain Research, 1127, 2007. Crossref

  140. Lee Joohyung, Di Marzo Vincenzo, Brotchie Jonathan M., A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats, Neuropharmacology, 51, 3, 2006. Crossref

  141. Muntoni Anna Lisa, Pillolla Giuliano, Melis Miriam, Perra Simona, Gessa Gian Luigi, Pistis Marco, Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons, European Journal of Neuroscience, 23, 9, 2006. Crossref

  142. De Vries Taco J., Shaham Yavin, Homberg Judith R., Crombag Hans, Schuurman Karianne, Dieben Jeanine, Vanderschuren Louk J.M.J., Schoffelmeer Anton N.M., A cannabinoid mechanism in relapse to cocaine seeking, Nature Medicine, 7, 10, 2001. Crossref

  143. Vries Taco J. De, Schoffelmeer Anton N.M., Cannabinoid CB1 receptors control conditioned drug seeking, Trends in Pharmacological Sciences, 26, 8, 2005. Crossref

  144. Berrendero Fernando, Castañé Anna, Ledent Catherine, Parmentier Marc, Maldonado Rafael, Valverde Olga, Increase of morphine withdrawal in mice lacking A2areceptors and no changes in CB1/A2adouble knockout mice, European Journal of Neuroscience, 17, 2, 2003. Crossref

  145. Duncan Marnie, Galic Michael A., Wang Arthur, Chambers Adam P., McCafferty Donna-Marie, McKay Derek M., Sharkey Keith A., Pittman Quentin J., Cannabinoid 1 receptors are critical for the innate immune response to TLR4 stimulation, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 305, 3, 2013. Crossref

  146. Fride Ester, Thiébot Marie-Hélène, Onaivi Emmanuel, Chaperon Frédérique, Behavioral Effects of Endocannabinoids, in Endocannabinoids, 2005. Crossref

  147. Onaivi Emmanuel S., Leonard Claire M., Ishiguro Hiroki, Zhang Ping Wu, Lin Zhicheng, Akinshola Babatunde E., Uhl George R., Endocannabinoids and cannabinoid receptor genetics, Progress in Neurobiology, 66, 5, 2002. Crossref

  148. Sarne Y, Keren O, Are cannabinoid drugs neurotoxic or neuroprotective?, Medical Hypotheses, 63, 2, 2004. Crossref

  149. Huestis Marilyn A., Boyd Susan J., Heishman Stephen J., Preston Kenzie L., Bonnet Denis, Le Fur Gerard, Gorelick David A., Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users, Psychopharmacology, 194, 4, 2007. Crossref

  150. Bortolato Marco, Bini Valentina, Tambaro Simone, Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis, Pharmaceuticals, 3, 9, 2010. Crossref

  151. Forman Lloyd J., The effect of cannabinoid receptor antagonism with SR141716A on antinociception induced by cocaine and the NMDA receptor antagonist, MK-801, Brain Research Bulletin, 61, 2, 2003. Crossref

  152. Sparling P. B., Giuffrida A., Piomelli D., Rosskopf L., Dietrich A., Exercise activates the endocannabinoid system, NeuroReport, 14, 17, 2003. Crossref

  153. Griebel Guy, Stemmelin Jeanne, Lopez-Grancha Mati, Fauchey Valérie, Slowinski Franck, Pichat Philippe, Dargazanli Gihad, Abouabdellah Ahmed, Cohen Caroline, Bergis Olivier E., The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents, Scientific Reports, 8, 1, 2018. Crossref

  154. De Vries Taco J., Homberg Judith R., Binnekade Rob, Raasø Halfdan, Schoffelmeer Anton N. M., Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats, Psychopharmacology, 168, 1-2, 2003. Crossref

  155. Grobin A. Chistina, VanDoren Margaret J., Porrino Linda J., Morrow A. Leslie, Cortical 3α-hydroxy-5α-pregnan-20-one levels after acute administration of Δ9-tetrahydrocannabinol, cocaine and morphine, Psychopharmacology, 179, 3, 2005. Crossref

  156. Whitney Osceola, Soderstrom Ken, Johnson Frank, CB1 cannabinoid receptor activation inhibits a neural correlate of song recognition in an auditory/perceptual region of the zebra finch telencephalon, Journal of Neurobiology, 56, 3, 2003. Crossref

  157. Arguello P. Alexander, Jentsch J. David, Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat, Psychopharmacology, 177, 1-2, 2004. Crossref

  158. Hampson Robert E., Simeral John D., Kelly Erica J., Deadwyler Sam A., Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons, Hippocampus, 13, 5, 2003. Crossref

  159. Justinova Zuzana, Animal Models of Cannabis Use Disorder, in Cannabis Use Disorders, 2019. Crossref

  160. Schuel Herbert, Burkman Lani J., Lippes Jack, Crickard Kent, Forester Ellyn, Piomelli Daniele, Giuffrida Andrea, N-Acylethanolamines in human reproductive fluids, Chemistry and Physics of Lipids, 121, 1-2, 2002. Crossref

  161. Biscaia Miguel, Marín Susana, Fernández Beatriz, Marco Eva M., Rubio Marina, Guaza Carmen, Ambrosio Emilio, Viveros Maria Paz, Chronic treatment with CP 55,940 during the peri-adolescent period differentially affects the behavioural responses of male and female rats in adulthood, Psychopharmacology, 170, 3, 2003. Crossref

  162. Melis Maria Rosaria, Succu Salvatora, Mascia Maria Stefania, Argiolas Antonio, Antagonism of cannabinoid CB1 receptors in the paraventricular nucleus of male rats induces penile erection, Neuroscience Letters, 359, 1-2, 2004. Crossref

  163. Desai Rajeev I., Thakur Ganesh A., Vemuri V. Kiran, Bajaj Shama, Makriyannis Alexandros, Bergman Jack, Analysis of Tolerance and Behavioral/Physical Dependence during Chronic CB1Agonist Treatment: Effects of CB1Agonists, Antagonists, and Noncannabinoid Drugs, Journal of Pharmacology and Experimental Therapeutics, 344, 2, 2013. Crossref

  164. Vogel Hans Gerhard, Analgesic, Anti-inflammatory, and Anti-pyretic Activity, in Drug Discovery and Evaluation, 2007. Crossref

  165. Nasehi Mohammad, Piri Morteza, Jamali-Raeufy Nida, Zarrindast Mohammad Reza, Influence of intracerebral administration of NO agents in dorsal hippocampus (CA1) on cannabinoid state-dependent memory in the step-down passive avoidance test, Physiology & Behavior, 100, 4, 2010. Crossref

  166. Kang Sinyoung, Kim Chi Hyo, Lee Heeseung, Kim Dong Yeon, Han Jong In, Chung Rack Kyung, Lee Guie Yong, Antinociceptive Synergy Between the Cannabinoid Receptor Agonist WIN 55,212-2 and Bupivacaine in the Rat Formalin Test, Anesthesia & Analgesia, 104, 3, 2007. Crossref

  167. Castle David J., Solowij Nadia, Acute and subacute psychomimetic effects of cannabis in humans, in Marijuana and Madness, 2004. Crossref

  168. Thiébot M. -H., Chaperon F., Effets comportementaux des cannabinoïdes Données animales, Douleur et Analgésie, 14, 4, 2001. Crossref

  169. Solinas Marcello, Yasar Sevil, Goldberg Steven R., Endocannabinoid system involvement in brain reward processes related to drug abuse, Pharmacological Research, 56, 5, 2007. Crossref

  170. Wenzel Jennifer M., Cheer Joseph F., Endocannabinoid-Dependent Modulation of Phasic Dopamine Signaling Encodes External and Internal Reward-Predictive Cues, Frontiers in Psychiatry, 5, 2014. Crossref

  171. Benamar Khalid, Yondorf Menachem, Meissler Joseph J., Geller Ellen B., Tallarida Ronald J., Eisenstein Toby K., Adler Martin W., A Novel Role of Cannabinoids: Implication in the Fever Induced by Bacterial Lipopolysaccharide, Journal of Pharmacology and Experimental Therapeutics, 320, 3, 2007. Crossref

  172. Muntoni Anna Lisa, Melis Miriam, Diana Marco, Electrophysiological Effects of Cannabinoids in the Basal Ganglia, in The Basal Ganglia VII, 52, 2002. Crossref

  173. Forget Benoît, Hamon Michel, Thiébot Marie-Hélène, Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats, Psychopharmacology, 181, 4, 2005. Crossref

  174. Chung Young C., Bok Eugene, Huh Sue H., Park Ju-Young, Yoon Sung-Hwa, Kim Sang R., Kim Yoon-Seong, Maeng Sungho, Hyun Park Sung, Jin Byung K., Cannabinoid Receptor Type 1 Protects Nigrostriatal Dopaminergic Neurons against MPTP Neurotoxicity by Inhibiting Microglial Activation, The Journal of Immunology, 187, 12, 2011. Crossref

  175. Catlow Briony, Sanchez-Ramos Juan, Cannabinoids for the Treatment of Movement Disorders, Current Treatment Options in Neurology, 17, 9, 2015. Crossref

  176. Brust John C.M., Marijuana, in Neurological Aspects of Substance Abuse, 2004. Crossref

  177. Vlachou Styliani, Nomikos George G., Panagis George, Effects of endocannabinoid neurotransmission modulators on brain stimulation reward, Psychopharmacology, 188, 3, 2006. Crossref

  178. Justinova Zuzana, Panlilio Leigh V., Goldberg Steven R., Drug Addiction, in Behavioral Neurobiology of the Endocannabinoid System, 1, 2009. Crossref

  179. Zarrindast Mohammad Reza, Dorrani Mania, Lachinani Razieh, Rezayof Ameneh, Blockade of dorsal hippocampal dopamine receptors inhibits state-dependent learning induced by cannabinoid receptor agonist in mice, Neuroscience Research, 67, 1, 2010. Crossref

  180. Valverde O., Karsak M., Zimmer A., Analysis of the Endocannabinoid System by Using CB1 Cannabinoid Receptor Knockout Mice, in Cannabinoids, 168, 2005. Crossref

  181. Robson P., Human Studies of Cannabinoids and Medicinal Cannabis, in Cannabinoids, 168, 2005. Crossref

  182. Jacobson Laura H., Commerford S. Renee, Gerber Sarah P., Chen Yu Alice, Dardik Beatriz, Chaperon Frederique, Schwartzkopf Chad, Nguyen-Tran Van, Hollenbeck Thomas, McNamara Peter, He Xiaohui, Liu Hong, Seidel H. Martin, Jaton Anne-Liese, Gromada Jesper, Teixeira Sandra, Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity, Naunyn-Schmiedeberg's Archives of Pharmacology, 384, 6, 2011. Crossref

  183. Roloff Alan M., Thayer Stanley A., Modulation of Excitatory Synaptic Transmission by Δ9-Tetrahydrocannabinol Switches from Agonist to Antagonist Depending on Firing Rate, Molecular Pharmacology, 75, 4, 2009. Crossref

  184. Lozovaya Natalia, Min Rogier, Tsintsadze Vera, Burnashev Nail, Dual modulation of CNS voltage-gated calcium channels by cannabinoids: Focus on CB1 receptor-independent effects, Cell Calcium, 46, 3, 2009. Crossref

  185. Lovell Peter V., Olson Christopher R., Mello Claudio V., Singing Under the Influence: Examining the Effects of Nutrition and Addiction on a Learned Vocal Behavior, Molecular Neurobiology, 44, 2, 2011. Crossref

  186. Page M.E., Oropeza V.C., Van Bockstaele E.J., Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex, Neuroscience Letters, 431, 1, 2008. Crossref

  187. McPARTLAND J. M., AGRAVAL J., GLEESON D., HEASMAN K., GLASS M., Cannabinoid receptors in invertebrates, Journal of Evolutionary Biology, 19, 2, 2006. Crossref

  188. Daniel Vino, Central Analgesic Activity, in Drug Discovery and Evaluation: Pharmacological Assays, 2016. Crossref

  189. Basavarajappa B. S., Yalamanchili R., Cooper T. B., Hungund B. L., The Endocannabinoid System, in Handbook of Neurochemistry and Molecular Neurobiology, 2008. Crossref

  190. Vinod K. Yaragudri, Yalamanchili Ratnakumar, Thanos Panayotis K., Vadasz Csaba, Cooper Thomas B., Volkow Nora D., Hungund Basalingappa L., Genetic and pharmacological manipulations of the CB1 receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice, Synapse, 62, 8, 2008. Crossref

  191. Abdel-Salam Omar M. E., Sleem Amany A., Mohamed Sayed Marawan Abd El-Baset, Youness Eman R., Shaffie Nermeen, Neuroprotective Effects of Low Dose Anandamide in Pentylenetetrazole-Induced Kindling in Rats, Biomedical and Pharmacology Journal, 12, 1, 2019. Crossref

  192. Iravani Mahmoud M., Jenner Peter, Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation, Journal of Neural Transmission, 118, 12, 2011. Crossref

  193. Bregman Tatiana, Fride Ester, Treatment with tetrahydrocannabinol (THC) prevents infertility in male cystic fibrosis mice, Journal of Basic and Clinical Physiology and Pharmacology, 22, 1-2, 2011. Crossref

  194. Bregman Tatiana, Fride Ester, Behavioral alterations in cystic fibrosis mice are prevented by cannabinoid treatment in infancy, Journal of Basic and Clinical Physiology and Pharmacology, 22, 1-2, 2011. Crossref

  195. Lichtman A. H., Martin B. R., Cannabinoid Tolerance and Dependence, in Cannabinoids, 168, 2005. Crossref

  196. Degroot Aldemar, Köfalvi Attila, Wade Mark R., Davis Richard J., Rodrigues Ricardo J., Rebola Nelson, Cunha Rodrigo A., Nomikos George G., CB1Receptor Antagonism Increases Hippocampal Acetylcholine Release: Site and Mechanism of Action, Molecular Pharmacology, 70, 4, 2006. Crossref

  197. Cha Hye Jin, Lee Kwang-Wook, Song Min-Ji, Hyeon Yang-Jin, Hwang Ji-Young, Jang Choon-Gon, Ahn Joon-Ik, Jeon Seol-Hee, Kim Hyun-Uk, Kim Young-Hoon, Seong Won-Keun, Kang Hoil, Yoo Han Sang, Jeong Ho-Sang, Dependence Potential of the Synthetic Cannabinoids JWH-073, JWH-081, and JWH-210: In Vivo and In Vitro Approaches, Biomolecules & Therapeutics, 22, 4, 2014. Crossref

  198. Roohbakhsh Ali, Moghaddam Akbar Hajizadeh, Massoudi Roohollah, Zarrindast Mohammad-Reza, ROLE OF DORSAL HIPPOCAMPAL CANNABINOID RECEPTORS AND NITRIC OXIDE IN ANXIETY LIKE BEHAVIOURS IN RATS USING THE ELEVATED PLUS-MAZE TEST, Clinical and Experimental Pharmacology and Physiology, 34, 3, 2007. Crossref

  199. Zavitsanou K., Wang H., Dalton V.S., Nguyen V., Cannabinoid administration increases 5HT1A receptor binding and mRNA expression in the hippocampus of adult but not adolescent rats, Neuroscience, 169, 1, 2010. Crossref

  200. El-Alfy Abir T., Wilson Lisa, ElSohly Mahmoud A., Abourashed Ehab A., Towards a better understanding of the psychopharmacology of nutmeg: Activities in the mouse tetrad assay, Journal of Ethnopharmacology, 126, 2, 2009. Crossref

  201. Soderstrom Ken, Tian Qiyu, CB1 cannabinoid receptor activation dose dependently modulates neuronal activity within caudal but not rostral song control regions of adult zebra finch telencephalon, Psychopharmacology, 199, 2, 2008. Crossref

  202. Colombo Graziano, Rusconi Francesco, Rubino Tiziana, Cattaneo Angela, Martegani Enzo, Parolaro Daniela, Bachi Angela, Zippel Renata, Transcriptomic and Proteomic Analyses of Mouse Cerebellum Reveals Alterations in RasGRF1 Expression Following In Vivo Chronic Treatment with Delta 9-Tetrahydrocannabinol, Journal of Molecular Neuroscience, 37, 2, 2009. Crossref

  203. Katz Paige S., Edwards Scott, Molina Patricia E., Cannabinoids, in Neuroinflammation and Neurodegeneration, 2014. Crossref

  204. Rawls S. M., Cabassa Jose, Geller Ellen B., Adler Martin W., CB1 Receptors in the Preoptic Anterior Hypothalamus Regulate WIN 55212-2 [(4,5-Dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-Induced Hypothermia, Journal of Pharmacology and Experimental Therapeutics, 301, 3, 2002. Crossref

  205. Schanzer Bella, Rivas-Grajales Ana Maria, Khan Aamir, Mathew Sanjay J, Novel investigational therapeutics for generalized anxiety disorder (GAD), Expert Opinion on Investigational Drugs, 28, 11, 2019. Crossref

  206. Geresu Berhanu, Canseco-Alba Ana, Sanabria Branden, Lin Zhicheng, Liu Qing-Rong, Onaivi Emmanuel S., Engidawork Ephrem, Involvement of CB2 Receptors in the Neurobehavioral Effects of Catha Edulis (Vahl) Endl. (Khat) in Mice, Molecules, 24, 17, 2019. Crossref

  207. Vaseghi Salar, Nasehi Mohammad, Zarrindast Mohammad-Reza, How do stupendous cannabinoids modulate memory processing via affecting neurotransmitter systems?, Neuroscience & Biobehavioral Reviews, 120, 2021. Crossref

  208. Amato George S., Manke Amruta, Harris Danni L., Wiethe Robert W., Vasukuttan Vineetha, Snyder Rodney W., Lefever Timothy W., Cortes Ricardo, Zhang Yanan, Wang Shaobin, Runyon Scott P., Maitra Rangan, Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor, Journal of Medicinal Chemistry, 61, 10, 2018. Crossref

  209. Raichlen David A., Foster Adam D., Gerdeman Gregory L., Seillier Alexandre, Giuffrida Andrea, Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the ‘runner’s high’, Journal of Experimental Biology, 215, 8, 2012. Crossref

  210. Lin Yu-Fung, Potassium channels as molecular targets of endocannabinoids, Channels, 15, 1, 2021. Crossref

  211. Patel Rikinkumar S., Gonzalez Mario D., Ajibawo Temitope, Baweja Raman, Cannabis use disorder and increased risk of arrhythmia‐related hospitalization in young adults, The American Journal on Addictions, 30, 6, 2021. Crossref

  212. Kesner Andrew J., Lovinger David M., Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings, Journal of Neurochemistry, 157, 5, 2021. Crossref

  213. Fuerte-Hortigón Alejando, Gonçalves Jaime, Zeballos Laura, Masa Rubén, Gómez-Nieto Ricardo, López Dolores E., Distribution of the Cannabinoid Receptor Type 1 in the Brain of the Genetically Audiogenic Seizure-Prone Hamster GASH/Sal, Frontiers in Behavioral Neuroscience, 15, 2021. Crossref

  214. El-Atawneh Shayma, Hirsch Shira, Hadar Rivka, Tam Joseph, Goldblum Amiram, Prediction and Experimental Confirmation of Novel Peripheral Cannabinoid-1 Receptor Antagonists, Journal of Chemical Information and Modeling, 59, 9, 2019. Crossref

  215. Tallett A. J., Blundell J. E., Rodgers R. J., Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats, Psychopharmacology, 195, 1, 2007. Crossref

  216. Hammad Alaa M., Meknas Sara Jamal, Hall F. Scott, Hikmat Suhair, Sari Youssef, Al-Qirim TM, Alfaraj Malek, Amawi Haneen, Effects of waterpipe tobacco smoke and ceftriaxone treatment on the expression of endocannabinoid receptors in mesocorticolimbic brain regions, Brain Research Bulletin, 185, 2022. Crossref

  217. Duraikkannu Durairaj, Chatterjee Nivedita, Endogenous Mediators of Neuroinflammation: The Endocannabinoid System at the Retina, in The Biology of Glial Cells: Recent Advances, 2022. Crossref

  218. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla G K, Pasquali R, Pagotto U, Endogenous cannabinoid system as a modulator of food intake, International Journal of Obesity, 27, 3, 2003. Crossref

  219. Blednov Y. A., Stoffel M., Alva H., Harris R. A., A pervasive mechanism for analgesia: Activation of GIRK2 channels, Proceedings of the National Academy of Sciences, 100, 1, 2003. Crossref

  220. Rahmani Mohammad-Reza, Shamsizadeh Ali, Moghadam-Ahmadi Amir, Bazmandegan Gholamreza, Allahtavakoli Mohammad, JZL184, as a monoacylglycerol lipase inhibitor, down-regulates inflammation in a cannabinoid pathway dependent manner, Biomedicine & Pharmacotherapy, 103, 2018. Crossref

  221. Paudel Pradeep, Ross Samir, Li Xing-Cong, Molecular Targets of Cannabinoids Associated with Depression, Current Medicinal Chemistry, 29, 11, 2022. Crossref

  222. Kim Byungwook, Park Ju-Young, Cho Duk-Yeon, Ko Hyun Myung, Yoon Sung-Hwa, Choi Dong-Kug, 2-(5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-N-(2-hydroxyethyl)-2-oxoacetamide (CDMPO) has anti-inflammatory properties in microglial cells and prevents neuronal and behavioral deficits in MPTP mouse model of Parkinson's disease, Neuropharmacology, 166, 2020. Crossref

  223. Varvel Stephen A., Martin Billy R., Lichtman Aron H., Lack of behavioral sensitization after repeated exposure to THC in mice and comparison to methamphetamine, Psychopharmacology, 193, 4, 2007. Crossref

  224. Mimura Takayuki, Ueda Yoshifumi, Watanabe Yoshihiro, Sugiura Takayuki, The cannabinoid receptor-2 is involved in allergic inflammation, Life Sciences, 90, 21-22, 2012. Crossref

  225. Robledo‐Menendez Almudena, Vella Maria, Grandes Pedro, Soria‐Gomez Edgar, Cannabinoid control of hippocampal functions: the where matters , The FEBS Journal, 289, 8, 2022. Crossref

  226. Kodas E., Cohen C., Louis C., Griebel G., Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling, Psychopharmacology, 194, 2, 2007. Crossref

  227. Daniel Vino, Central Analgesic Activity, in Drug Discovery and Evaluation: Pharmacological Assays, 2014. Crossref

Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain